Pulse Biosciences, Inc.
Financials
Valuation Metrics
Pulse Biosciences, Inc.'s Market Cap is $3.77B. At end of 2025 it was $925M. Ranked #1555 of 3,118 in US market (top 50%), #537 of 1,474 on NASDAQ (top 36%), #100 of 203 in Health Care Equipment & Services (top 49%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.77B | US#1,555/3,118 Sec#100/203 |
| Revenue | $1M | US#2,844/3,118 Sec#199/203 |
| Net Income | $-80M | US—/3,118 Sec—/203 |
| Total Assets | $116M | US#3,042/3,118 Sec#197/203 |
| Net Assets | $100M | US#2,797/3,118 Sec#180/203 |
| Employees | 116 | US#2,583/3,118 Sec#180/203 |
| Value | ||
| P/B | 37.92x | US#2,867/3,118 Sec#190/203 |
| P/S | 10779.90x | US#2,994/3,118 Sec#204/203 |
| FCF Yield | -1.63% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -80.46% | US#2,762/3,118 Sec#177/203 |
| ROA | -69.27% | US#3,025/3,118 Sec#200/203 |
| Op. Margin | -7007.76% | US#2,838/3,118 Sec#199/203 |
| Financial Health | ||
| Debt Ratio | 16.14% | US#182/3,118 Sec#16/203 |
| Total Debt | $7M | US#2,857/3,118 Sec#192/203 |
| FCF | $-61M | US#2,548/3,118 Sec#182/203 |
| Cash | $102M | US#2,220/3,118 Sec#137/203 |
| Current Ratio | 9.63x | US#257/3,118 Sec#11/203 |
| Performance | ||
| 1Y Return | 212.46% | US#30/3,118 Sec#7/203 |
| 1M Return | 10.44% | US#1,284/3,118 Sec#108/203 |
| From 52W High | -10.19% | US#897/3,118 Sec#75/203 |
| 1Y MDD | -29.50% | US#1,260/3,118 Sec#62/203 |
| Trading | ||
| Volume | 212,492 shares | US#2,113/3,118 Sec#149/203 |
| Trading Value | $11M | US#1,760/3,118 Sec#119/203 |
| Per Share | ||
| EPS | $-1.12 | US—/3,118 Sec—/203 |
| BPS | $1.40 | US#2,636/3,118 Sec#173/203 |
Company Info
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.